Clinical trials: Appendix
Healthy
A Study Exploring the Use of Challenge Agents in Healthy Volunteers - Intervention Specific Appendix
The purpose of this study is to characterize the disruption of intestinal barrier as a result of indomethacin challenge in healthy volunteers using an orally administered lactulose-mannitol test.
- Trial name
- NCT04821323
- Testing
- Indomethacin, Lactulose-mannitol
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
- Trial name
- NCT04611971
- Testing
- Benlysta, Candin
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
- Trial name
- PLATFORM (NCT04589026)
- Testing
- Cosentyx, Candin
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
- Trial name
- NCT05522517
- Testing
- Cosentyx, Candin
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
The purpose of the study is to characterize the inflammatory response to lipopolysaccharide (LPS; molecules that contains fats and carbohydrates) in the presence of a targeted immune pathway modulator.
- Trial name
- NCT05884242
- Testing
- Adalimumab, Lipopolysaccharide (LPS)
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Allergic Sensitization
Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100
Patch Testing for device cream on human subjects
- Trial name
- RIPT (NCT03450070)
- Testing
- Light Therapy Mask Cream
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.